June 28, 2012

Rita E. Numerof, Ph.D., President of Numerof & Associates, Inc., joined other industry experts as a panelist at the Orphan Disease Forum – Innovations in Supply Chain Economics and Value Creation in U.S. Orphan Markets at the BIO International Convention on June 19.

Because orphan drug products carry a higher per-patient cost than other drugs, their manufacturers are challenged to demonstrate their value. During her session, Dr. Numerof shared what payers are really looking for, and how manufacturers can collect the data they need to ensure market access.